UK–US Arrangement — Relevance to Northern Ireland

The VPAG rebate is negotiated on behalf of all four UK nations. The reduction of the VPAG rebate from 22.9% to 14.5% therefore applies to NI as does the commitment to increase spending on innovative medicines from 0.3% to 0.6% of GDP. Northern Ireland endorses NICE technology appraisals through a separate DoH NI process. The […]

DoH NI MEDICINES ACCESS REVIEW — RECOMMENDATION 2

The DoH NI Medicines Access Review (2025) specifically names the Blueteq HCD system as the recommended replacement for cost-per-case commissioning.

Medicines Access Review — Implementation

No formal announcement of progress against the ten recommendations of the 2025 Medicines Access Review has been published during May 2026. DoH NI Consultations A DoH NI consultation opened on 11 May 2026 relating to proposed changes to UK-wide medicines legislation governing the definition of gene therapies, led by the MHRA. This is not directly […]